Upstream Bio Inc (UPB)

$27.74 +0.77 (2.86%)
Market Cap 1.35B
Revenue (ttm) 2.37M
Net Income (ttm) -62.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,650.21%
Debt to Equity Ratio 0.00
Volume 568,400
Avg Vol 413,110
Day's Range N/A - N/A
Shares Out 54.04M
Stochastic %K 41%
Beta 1.83
Analysts Strong Sell
Price Target $49.25

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
Iightning
Iightning Dec. 4 at 10:54 PM
1ightning® Premium Options Alert (Actionable) Ticker: $UPB Contract: Dec 19 $25C Entry: 3.77 Exit: 7.09 Return: +87.81% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 6:36 AM
1ightning® Premium Options Alert (Actionable) Ticker: $UPB Contract: Dec 19 $25C Entry: 2.70 Exit: 4.31 Return: +59.69% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 10:11 AM
1ightning® Premium Options Alert (Actionable) Ticker: $UPB Contract: Dec 19 $17.5C Entry: 11.50 Exit: 14.29 Return: +24.27% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 12:54 PM
LifeSci Capital updates rating for Upstream Bio ( $UPB ) to Outperform, target set at 43.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:57 AM
$UNG $UNX $UPB $UPGR $UPRO
0 · Reply
Iightning
Iightning Dec. 2 at 12:53 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $UPB **Contract:** Dec 19 $30C **Entry:** 1.78 **Exit:** 2.18 **Return:** **+22.90% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Trainguy1
Trainguy1 Nov. 26 at 2:34 PM
$UPB FYI, see my brief write-up below that indicates how Verekitug stops asthma.
0 · Reply
Iightning
Iightning Nov. 26 at 3:47 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.87 Exit: $4.19 | Profit: 45.89% ROI | https://1ightning.com
0 · Reply
S2K_TP
S2K_TP Nov. 26 at 2:45 AM
$UPB momentum play ✈️
0 · Reply
StockConsultant
StockConsultant Nov. 25 at 8:50 PM
$UPB Upstream Bio stock, good breakout, from Stocks to Watch at https://stockconsultant.com/?UPB
1 · Reply
Latest News on UPB
Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 25, 2025, 7:00 AM EST - 9 days ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio to Participate in Upcoming November Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 4 weeks ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 30, 2025, 4:15 AM EDT - 2 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 3 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio, Inc. - Special Call

Sep 7, 2025, 10:25 PM EDT - 3 months ago

Upstream Bio, Inc. - Special Call

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 2, 2025, 6:00 AM EDT - 3 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 3 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio (UPB) Q2 R&D Soars 169%

Aug 6, 2025, 9:06 PM EDT - 4 months ago

Upstream Bio (UPB) Q2 R&D Soars 169%

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Aug 6, 2025, 7:00 AM EDT - 4 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jul 8, 2025, 7:00 AM EDT - 5 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 15, 2025, 7:45 AM EDT - 6 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 5, 2025, 7:00 AM EDT - 6 months ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 6 months ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 7 months ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

May 6, 2025, 7:00 AM EDT - 7 months ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Apr 17, 2025, 5:51 PM EDT - 8 months ago

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

3 Dividend Giants To Buy As Tariffs Hit Stocks

Mar 28, 2025, 3:56 PM EDT - 8 months ago

3 Dividend Giants To Buy As Tariffs Hit Stocks

PEP PG

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 12, 2025, 7:00 AM EDT - 9 months ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 10 months ago

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Dec 16, 2024, 1:03 PM EST - 1 year ago

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Nov 5, 2024, 3:09 PM EST - 1 year ago

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Iightning
Iightning Dec. 4 at 10:54 PM
1ightning® Premium Options Alert (Actionable) Ticker: $UPB Contract: Dec 19 $25C Entry: 3.77 Exit: 7.09 Return: +87.81% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 6:36 AM
1ightning® Premium Options Alert (Actionable) Ticker: $UPB Contract: Dec 19 $25C Entry: 2.70 Exit: 4.31 Return: +59.69% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 10:11 AM
1ightning® Premium Options Alert (Actionable) Ticker: $UPB Contract: Dec 19 $17.5C Entry: 11.50 Exit: 14.29 Return: +24.27% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 12:54 PM
LifeSci Capital updates rating for Upstream Bio ( $UPB ) to Outperform, target set at 43.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:57 AM
$UNG $UNX $UPB $UPGR $UPRO
0 · Reply
Iightning
Iightning Dec. 2 at 12:53 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $UPB **Contract:** Dec 19 $30C **Entry:** 1.78 **Exit:** 2.18 **Return:** **+22.90% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Trainguy1
Trainguy1 Nov. 26 at 2:34 PM
$UPB FYI, see my brief write-up below that indicates how Verekitug stops asthma.
0 · Reply
Iightning
Iightning Nov. 26 at 3:47 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.87 Exit: $4.19 | Profit: 45.89% ROI | https://1ightning.com
0 · Reply
S2K_TP
S2K_TP Nov. 26 at 2:45 AM
$UPB momentum play ✈️
0 · Reply
StockConsultant
StockConsultant Nov. 25 at 8:50 PM
$UPB Upstream Bio stock, good breakout, from Stocks to Watch at https://stockconsultant.com/?UPB
1 · Reply
Doozio
Doozio Nov. 25 at 8:31 PM
$UPB huckleberries r thru da $$$$. 🐒🍌🧠⏰♾️
0 · Reply
Iightning
Iightning Nov. 25 at 1:53 PM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.87 Exit: $4.19 | Profit: 45.89% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:45 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.87 Exit: $4.19 | Profit: 45.89% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 24 at 1:48 PM
$UNG $UNX $UPB $UPGR $UPRO
0 · Reply
Iightning
Iightning Nov. 22 at 12:01 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.85 Exit: $3.84 | Profit: 35.12% ROI | https://1ightning.com
0 · Reply
Doozio
Doozio Nov. 21 at 11:47 PM
$UPB if no faatch 💣 lands it’s heading ♾️
0 · Reply
Iightning
Iightning Nov. 21 at 3:22 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.85 Exit: $3.84 | Profit: 35.12% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 12:46 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.85 Exit: $3.84 | Profit: 35.12% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 8:58 AM
1ightning® Options Trade Alert (Actionable) | Buy $UPB Dec 19 $25 Call | Enter: $2.85 Exit: $3.84 | Profit: 35.12% ROI | https://1ightning.com
0 · Reply
StockConsultant
StockConsultant Nov. 18 at 1:49 PM
$UPB Upstream Bio stock, good day, watch for a top of range breakout at https://stockconsultant.com/?UPB
1 · Reply
JarvisFlow
JarvisFlow Nov. 18 at 12:40 PM
Evercore ISI Group updates rating for Upstream Bio ( $UPB ) to Outperform, target set at 40.
0 · Reply
Quantumup
Quantumup Nov. 18 at 11:39 AM
Evercore ISI🏁 $UPB Outperform/$40 $REGN - $SNY $AZN - $AMGN Evercore ISI in its initiation report said: UPB's sole program, verekitug, is going after multi-billion-$ indications (i.e. asthma, COPD) that have made drugs like REGN's Dupixent & AMGN/AZN's Tezspire into well-known blockbusters. Verekitug taps a validated MOA, offers a more convenient dosing schedule, and could potentially enable superior efficacy over current TSLP targeting agents. Recent positive clinical results from the VIBRANT Ph2 trial in CRSwNP further validates verekitug's pot'I. With a key Ph2 asthma readout (VALIANT) on tap for 1Q26, strong data could be a meaningful upside catalyst. Initiate OP; $40 YE26 PT.
0 · Reply